MNTA – That’s a weak article from the MF, IMO. I do not see any parallels between VPHM’s Vancocin case and the generic-Lovenox ANDA from NVS/MNTA other than the fact that both are being handled by the FDA’s Office of Generic Drugs (OGD).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”